Fracture Liaison Service Updates

Only available as part of a package

Fracture Liaison Services are crucial to helping prevent future fractures in very high risk patients. The ideal way in which to implement this service remains debatable. The success and data available on the current FLS program being implemented at MGH to date with the use of Zoledronate early on will be discussed.

OBJECTIVES
  1. Recognize FLS as an effective mechanism to narrow osteoporosis treatment gap and fracture secondary prevention as a critical opportunity to identify and treat at-risk patients
  2. Evaluate the safety of zoledronic acid administered during initial fracture hospitalization and its effectiveness in improving osteoporosis treatment rate
  3. Discuss clinical outcomes of inpatient zoledronic acid for patients admitted for hip fracture
LOCATION

Georgian room

WuQiang Fan

Clinical Director of Fracture Liaison Service

Massachusetts General Hospital

Dr. WuQiang Fan graduated from Zhejiang University School of Medicine in China and obtained a PhD degree in molecular biology at Kyushu University in Japan. He completed his residency training in medicine at Drexel University in Pennsylvania and subsequently joined MGH endocrine fellowship program in 2016.

He is currently a faculty member of the MGH Endocrine division and serves as the clinical director of the MGH Fracture Liaison Service and fracture secondary prevention program since July 2021.

This activity has been approved by ASRT for 1.0 Category A continuing education credits.

If you want to claim credits for ACCME you will be able to at the end of the conference at this link:
https://learn.iscd.org/product...

Components visible upon registration.
;